Heath-Chiozzi Margo

SEC source: 0001718112-26-000002 · form4-06292026_080629.xml · derivative · entry 1

Heath-Chiozzi Margo · CIK 0001718112 · SVP OF REGULATORY AFFAIRS

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 95,000

Underlying: Common Stock · 95,000 shares

Expires 2036-06-25

F1 · security: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan.

F1 · date: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan.

F2 · derivative.exercise_date: 25% vest on June 25, 2027 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters.

SEC source: 0001415889-25-016255 · form4-06092025_080648.xml · derivative · entry 1

Heath-Chiozzi Margo · CIK 0001718112 · SVP OF REGULATORY AFFAIRS

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 82,000

Underlying: Common Stock · 82,000 shares

Expires 2035-06-05

F1 · security: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan.

F1 · date: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan.

F2 · derivative.exercise_date: 25% vest on June 5, 2026 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters.

SEC source: 0001415889-24-017184 · form4-06172024_080655.xml · derivative · entry 1

Heath-Chiozzi Margo · CIK 0001718112 · SVP OF REGULATORY AFFAIRS

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 82,000

Underlying: Common Stock · 82,000 shares

Expires 2034-06-13

F1 · security: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan.

F1 · date: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan.

F2 · derivative.exercise_date: 25% vest on June 13, 2025 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters.

SEC source: 0001415889-24-015544 · form4-06052024_080636.xml · derivative · entry 5

Heath-Chiozzi Margo · CIK 0001718112 · SVP OF REGULATORY AFFAIRS

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 23,023

Underlying: Common Stock · 58,369 shares

Expires 2030-06-18

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: 25% vested on June 18, 2021 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters.

SEC source: 0001415889-24-015544 · form4-06052024_080636.xml · derivative · entry 4

Heath-Chiozzi Margo · CIK 0001718112 · SVP OF REGULATORY AFFAIRS

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 6,289 shares

Expires 2028-06-13

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: As of June 13, 2022, the option is fully vested.

SEC source: 0001415889-24-015544 · form4-06052024_080636.xml · nonDerivative · entry 3

Heath-Chiozzi Margo · CIK 0001718112 · SVP OF REGULATORY AFFAIRS

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 13,383

F1 · kind: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.27 to $34.08 per share, inclusive. The reporting person undertakes to provide to Celldex Therapeutics, Inc., any security holder of Celldex Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.

F1 · shares: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.27 to $34.08 per share, inclusive. The reporting person undertakes to provide to Celldex Therapeutics, Inc., any security holder of Celldex Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.

F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.27 to $34.08 per share, inclusive. The reporting person undertakes to provide to Celldex Therapeutics, Inc., any security holder of Celldex Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.

SEC source: 0001415889-24-015544 · form4-06052024_080636.xml · nonDerivative · entry 2

Heath-Chiozzi Margo · CIK 0001718112 · SVP OF REGULATORY AFFAIRS

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 71,752

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001415889-24-015544 · form4-06052024_080636.xml · nonDerivative · entry 1

Heath-Chiozzi Margo · CIK 0001718112 · SVP OF REGULATORY AFFAIRS

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 13,383

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001415889-24-015148 · form4-06032024_080622.xml · derivative · entry 7

Heath-Chiozzi Margo · CIK 0001718112 · SVP OF REGULATORY AFFAIRS

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 81,392

Underlying: Common Stock · 2,608 shares

Expires 2030-06-18

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · derivative.exercise_date: 25% vested on June 18, 2021 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters.

SEC source: 0001415889-24-015148 · form4-06032024_080622.xml · derivative · entry 6

Heath-Chiozzi Margo · CIK 0001718112 · SVP OF REGULATORY AFFAIRS

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,289

Underlying: Common Stock · 2,043 shares

Expires 2028-06-13

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: As of June 13, 2022, the option is fully vested.

SEC source: 0001415889-24-015148 · form4-06032024_080622.xml · derivative · entry 5

Heath-Chiozzi Margo · CIK 0001718112 · SVP OF REGULATORY AFFAIRS

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,732

Underlying: Common Stock · 29,068 shares

Expires 2029-06-19

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: As of June 19, 2023, the option is fully vested.

SEC source: 0001415889-24-015148 · form4-06032024_080622.xml · nonDerivative · entry 4

Heath-Chiozzi Margo · CIK 0001718112 · SVP OF REGULATORY AFFAIRS

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,094

F2 · kind: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.850 to $34.445 per share, inclusive. The reporting person undertakes to provide to Celldex Therapeutics, Inc., any security holder of Celldex Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.

F2 · shares: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.850 to $34.445 per share, inclusive. The reporting person undertakes to provide to Celldex Therapeutics, Inc., any security holder of Celldex Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.850 to $34.445 per share, inclusive. The reporting person undertakes to provide to Celldex Therapeutics, Inc., any security holder of Celldex Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.

SEC source: 0001415889-24-015148 · form4-06032024_080622.xml · nonDerivative · entry 3

Heath-Chiozzi Margo · CIK 0001718112 · SVP OF REGULATORY AFFAIRS

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 45,813

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001415889-24-015148 · form4-06032024_080622.xml · nonDerivative · entry 2

Heath-Chiozzi Margo · CIK 0001718112 · SVP OF REGULATORY AFFAIRS

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 43,205

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001415889-24-015148 · form4-06032024_080622.xml · nonDerivative · entry 1

Heath-Chiozzi Margo · CIK 0001718112 · SVP OF REGULATORY AFFAIRS

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 41,162

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: Includes 847 shares of common stock acquired under the Celldex Therapeutics, Inc. 2004 Employee Stock Purchase Plan.

SEC source: 0001415889-23-010044 · form4-06202023_080633.xml · derivative · entry 1

Heath-Chiozzi Margo · CIK 0001718112 · SVP OF REGULATORY AFFAIRS

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 80,000

Underlying: Common Stock · 80,000 shares

Expires 2033-06-15

F1 · security: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan.

F1 · date: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan.

F2 · derivative.exercise_date: 25% vest on June 15, 2024 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters.

SEC source: 0001415889-22-006728 · form4-06172022_010602.xml · derivative · entry 1

Heath-Chiozzi Margo · CIK 0001718112 · SVP OF REGULATORY AFFAIRS

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 77,000

Underlying: Common Stock · 77,000 shares

Expires 2032-06-16

F1 · security: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan.

F1 · date: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan.

F2 · derivative.exercise_date: 25% vest on June 16, 2023 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters.

SEC source: 0001179110-21-010818 · edgar.xml · derivative · entry 3

Heath-Chiozzi Margo · CIK 0001718112 · SVP of Regulatory Affairs

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 41,800

Underlying: Common Stock · 600 shares

Expires 2029-06-19

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: 25 % vested on June 19, 2020 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters.

SEC source: 0001179110-21-010818 · edgar.xml · nonDerivative · entry 2

Heath-Chiozzi Margo · CIK 0001718112 · SVP of Regulatory Affairs

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,247

F1 · kind: The sale of the shares of Common Stock were made pursuant to a plan intended to comply with Rule 10b5-1 of the Exchange Act, previously entered into on August 13, 2021.

F1 · shares: The sale of the shares of Common Stock were made pursuant to a plan intended to comply with Rule 10b5-1 of the Exchange Act, previously entered into on August 13, 2021.

SEC source: 0001179110-21-010818 · edgar.xml · nonDerivative · entry 1

Heath-Chiozzi Margo · CIK 0001718112 · SVP of Regulatory Affairs

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,847

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001179110-21-009815 · edgar.xml · derivative · entry 3

Heath-Chiozzi Margo · CIK 0001718112 · SVP of Regulatory Affairs

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 42,400

Underlying: Common Stock · 600 shares

Expires 2029-06-19

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: 25 % vested on June 19, 2020 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters.

SEC source: 0001179110-21-009815 · edgar.xml · nonDerivative · entry 2

Heath-Chiozzi Margo · CIK 0001718112 · SVP of Regulatory Affairs

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,247

F1 · kind: The sale of the shares of Common Stock were made pursuant to a plan intended to comply with Rule 10b5-1 of the Exchange Act, previously entered into on August 13, 2021.

F1 · shares: The sale of the shares of Common Stock were made pursuant to a plan intended to comply with Rule 10b5-1 of the Exchange Act, previously entered into on August 13, 2021.

SEC source: 0001179110-21-009815 · edgar.xml · nonDerivative · entry 1

Heath-Chiozzi Margo · CIK 0001718112 · SVP of Regulatory Affairs

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,847

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001179110-21-008164 · edgar.xml · derivative · entry 2

Heath-Chiozzi Margo · CIK 0001718112 · SVP of Regulatory Affairs

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,332

Underlying: Common Stock · 10,000 shares

Expires 2028-06-13

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: This option was previously reported as covering 275,000 shares at an exercise price of $0.6011 per share, but has been adjusted to reflect the Reverse Stock Split.

F3 · derivative.exercise_date: 25% vested on June 13, 2019 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters

F2 · balance_after: This option was previously reported as covering 275,000 shares at an exercise price of $0.6011 per share, but has been adjusted to reflect the Reverse Stock Split.

SEC source: 0001179110-21-008164 · edgar.xml · nonDerivative · entry 1

Heath-Chiozzi Margo · CIK 0001718112 · SVP of Regulatory Affairs

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,247

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · price: This option was previously reported as covering 275,000 shares at an exercise price of $0.6011 per share, but has been adjusted to reflect the Reverse Stock Split.

F1 · balance_after: Includes 247 shares of common stock acquired under the Celldex Therapeutics, Inc. 2004 Employee Stock Purchase Plan. On February 8, 2019, Celldex Therapeutics, Inc. effected a 1-for-15 reverse stock split of its common stock (the "Reverse Stock Split"). The amount of securities reported on this Form 4 have been adjusted to reflect the Reverse Stock Split.

SEC source: 0001179110-21-006910 · edgar.xml · derivative · entry 1

Heath-Chiozzi Margo · CIK 0001718112 · SVP of Regulatory Affairs

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 62,500

Underlying: Common Stock · 62,500 shares

Expires 2031-06-17

F1 · security: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan.

F2 · derivative.exercise_date: 25% vest on June 17, 2022 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters.

SEC source: 0001179110-20-007597 · edgar.xml · derivative · entry 1

Heath-Chiozzi Margo · CIK 0001718112 · SVP of Regulatory Affairs

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 84,000

Underlying: Common Stock · 84,000 shares

Expires 2030-06-18

F1 · security: Represents option granted by the Issuer pursuant to its 2008 Stock Option and Incentive Plan.

F2 · derivative.exercise_date: 25% vest on June 18, 2021 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters.

SEC source: 0001179110-20-007167 · edgar.xml · nonDerivative · entry 1

Heath-Chiozzi Margo · CIK 0001718112 · SVP of Regulatory Affairs

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,000

SEC source: 0001179110-19-007977 · edgar.xml · derivative · entry 1

Heath-Chiozzi Margo · CIK 0001718112 · SVP of Regulatory Affairs

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 43,000

Underlying: Common Stock · 43,000 shares

Expires 2029-06-19

F1 · security: Represents option granted by the Issuer pursuant to its 2008 Stock Option and Incentive Plan.

F2 · derivative.exercise_date: 25% vest on June 19, 2020 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters.

SEC source: 0001179110-18-008570 · edgar.xml · derivative · entry 1

Heath-Chiozzi Margo · CIK 0001718112 · SVP of Regulatory Affairs

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 275,000

Underlying: Common Stock · 275,000 shares

Expires 2028-06-13

F1 · security: Represents option granted by the Issuer pursuant to its 2008 Stock Option and Incentive Plan.

F2 · derivative.exercise_date: 25% vest on June 13, 2019 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters.

SEC source: 0000905718-17-000863 · chiozzi_fm4oct32017.xml · derivative · entry 1

Heath-Chiozzi Margo · CIK 0001718112 · SVP of Regulatory Affairs

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 75,000

Underlying: Common Stock · 75,000 shares

Expires 2027-10-03

F1 · security: Represents option granted by Issuer pursuant to its 2008 Stock Option and Incentive Plan.

F2 · derivative.exercise_date: 25% vest on October 3, 2018 and the remainder vests quarterly (in equal amounts) over the subsequent 12 quarters.